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by inhibition of the mevalonate–isoprenoid 
pathway. See pages 571 and 577.
Intravenous 
bisphosphonates  
and renal risk
Intravenous (i.v.) bisphosphonates reduce 
the risk of fractures; in rare instances, they 
also cause renal function to deteriorate. In 
a large, placebo-controlled, double-blind 
trial, postmenopausal women were given 
i.v. administration of the bisphosphonate 
zoledronic acid. Boonen et al. found a 
significant increase in serum creatinine 
in those who received the drug. However, 
the increase was transient; all subjects 
recovered their pre-infusion levels of 
Statins and  
renal disease
Statins, widely used to lower cholesterol 
by inhibiting 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase, have 
also been shown to have salutary effects 
on many seemingly unrelated processes. 
A Review by Fried in this issue discusses 
these positive effects, including slowing of 
the progression of CKD and reduction of 
renal injury following ischemia and reper-
fusion. Are these effects part of the HMG-
CoA inhibition, or are they ‘idiosyncratic’? 
To investigate this, Sharyo et al., as they 
report in an original Article, induced 
the production of ischemia–reperfusion 
injury in mice and found that treatment 
with a statin improved renal function after 
ischemia–reperfusion without lowering 
levels of plasma cholesterol. However, 
when they simultaneously administered 
mevalonate, the product of HMG-CoA 
reductase activity, with the statin, renal 
protection was eliminated. When they 
used hypercholesterolemic apoE knock-
out mice that had reduced HMG-CoA 
reductase activity, statins had no protec-
tive effect, but ischemic injury was milder 
in the knockout mice than in wild-type 
mice. Inhibition of farnesyltransferase, an 
enzyme that generates isoprenoid com-
pounds, also protected against renal injury, 
but statin coadministration provided no 
additional protective effect. The work of 
Sharyo et al. provides strong evidence that 
the protective effect of statins is mediated 
serum creatinine within one year. Hence, 
although it appears that i.v. zoledronate 
causes a decline in renal function, this 
decline does not appear to be long-term. 
See page 641.
High alkaline 
phosphatase in 
dialysis patients
Using the results of a large, prospective, 
longitudinal study of patients on hemo-
dialysis in 12 countries, Blayney et al. 
evaluated their risk of elevated alkaline 
phosphatase levels. High alkaline phos-
phatase levels were significantly associated 
with increased risk of several comorbid 
conditions, including fractures, parathy-
roidectomy, hospitalization due to major 
adverse cardiac events, and all-cause car-
diovascular and infection-related mor-
tality. Further, the odds of having high 
alkaline phosphatase levels were twice 
as high for dialysis patients in the United 
States as for dialysis patients in Japan. 
See page 655.
